Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
07
2022
accepted:
29
10
2022
entrez:
30
12
2022
pubmed:
31
12
2022
medline:
4
1
2023
Statut:
epublish
Résumé
Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on skin and gut microbiota composition, specific immune response to commensals, and various serum biomarkers. We recruited 11 patients with IBD who were monitored over 40 weeks of ustekinumab therapy and 39 healthy controls (HC). We found differences in the concentrations of serum levels of osteoprotegerin, TGF-β1, IL-33, and serum IgM antibodies against Lactobacillus plantarum between patients with IBD and HC. The levels of these biomarkers did not change in response to ustekinumab treatment or with disease improvement during the 40 weeks of observation. Additionally, we identified differences in stool abundance of uncultured Subdoligranulum, Faecalibacterium, and Bacteroides between patients with IBD and HC. In this preliminary study, we provide a unique overview of the longitudinal monitoring of fecal and skin microbial profiles as well as various serum biomarkers and humoral and cellular response to gut commensals in a small cohort of patients with IBD on ustekinumab therapy.
Sections du résumé
BACKGROUND
Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on skin and gut microbiota composition, specific immune response to commensals, and various serum biomarkers.
METHODOLOGY/PRINCIPAL FINDINGS
We recruited 11 patients with IBD who were monitored over 40 weeks of ustekinumab therapy and 39 healthy controls (HC). We found differences in the concentrations of serum levels of osteoprotegerin, TGF-β1, IL-33, and serum IgM antibodies against Lactobacillus plantarum between patients with IBD and HC. The levels of these biomarkers did not change in response to ustekinumab treatment or with disease improvement during the 40 weeks of observation. Additionally, we identified differences in stool abundance of uncultured Subdoligranulum, Faecalibacterium, and Bacteroides between patients with IBD and HC.
CONCLUSION/SIGNIFICANCE
In this preliminary study, we provide a unique overview of the longitudinal monitoring of fecal and skin microbial profiles as well as various serum biomarkers and humoral and cellular response to gut commensals in a small cohort of patients with IBD on ustekinumab therapy.
Identifiants
pubmed: 36584073
doi: 10.1371/journal.pone.0277576
pii: PONE-D-22-19325
pmc: PMC9803183
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
Tumor Necrosis Factor Inhibitors
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0277576Informations de copyright
Copyright: © 2022 Rob et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Med (Lausanne). 2020 Sep 02;7:517
pubmed: 32984386
Biomed Pharmacother. 2021 Sep;141:111904
pubmed: 34328113
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
pubmed: 12883005
J Chin Med Assoc. 2021 Jun 1;84(6):580-587
pubmed: 33871395
ISRN Inflamm. 2014 Mar 25;2014:928461
pubmed: 25101191
Gut. 2017 Jun;66(6):1039-1048
pubmed: 26843508
Aliment Pharmacol Ther. 2000 Nov;14(11):1443-9
pubmed: 11069315
J Crohns Colitis. 2020 Jun 19;14(5):694-709
pubmed: 31777929
Sci Rep. 2018 Sep 19;8(1):14069
pubmed: 30232462
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):185-196
pubmed: 30478416
Gut. 2013 Dec;62(12):1714-23
pubmed: 23172891
Gastroenterology. 2021 Aug;161(2):522-535.e6
pubmed: 33844987
J Transl Autoimmun. 2020 Jan 26;3:100036
pubmed: 32743520
Sci Rep. 2019 Dec 11;9(1):18880
pubmed: 31827191
Inflamm Bowel Dis. 2009 Aug;15(8):1183-9
pubmed: 19235886
Am J Physiol Gastrointest Liver Physiol. 2015 Feb 1;308(3):G161-70
pubmed: 25477373
FEMS Microbiol Rev. 2017 Jul 1;41(4):479-511
pubmed: 28430946
J Exp Clin Cancer Res. 2019 Jan 8;38(1):12
pubmed: 30621730
Gut. 2021 Mar;70(3):499-510
pubmed: 32536605
Gastroenterology. 2005 Jun;128(7):2020-8
pubmed: 15940634
Indian J Microbiol. 2017 Sep;57(3):307-315
pubmed: 28904415
ISME J. 2017 Apr;11(4):841-852
pubmed: 28045459
Front Microbiol. 2021 Jun 08;12:598232
pubmed: 34168621
J Exp Med. 2005 Jul 4;202(1):135-43
pubmed: 15998792
Aliment Pharmacol Ther. 2022 Jan;55(1):26-48
pubmed: 34751954
Gut Pathog. 2020 Jan 04;12:1
pubmed: 31911822
Biochem Biophys Res Commun. 1998 Jun 29;247(3):610-5
pubmed: 9647741
mSphere. 2018 Mar 28;3(2):
pubmed: 29600282
Clin Exp Immunol. 2004 Dec;138(3):491-8
pubmed: 15544627
Clin Vaccine Immunol. 2012 Apr;19(4):515-21
pubmed: 22336288
Immunity. 2019 Apr 16;50(4):1099-1114.e10
pubmed: 30876876
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
pubmed: 18936492
Dig Dis Sci. 2021 May;66(5):1631-1638
pubmed: 32445049
Gastroenterology. 2017 Nov;153(5):1320-1337.e16
pubmed: 28782508
Am J Gastroenterol. 2008 Feb;103(2):386-96
pubmed: 17924999
Inflamm Bowel Dis. 2015 Aug;21(8):1948-56
pubmed: 26083617
Gastroenterology. 2021 Jan;160(2):524-537
pubmed: 33253681
J Crohns Colitis. 2020 Sep 7;14(8):1149-1161
pubmed: 32090263
J Clin Invest. 2022 Mar 1;132(5):
pubmed: 35229726
J Gastroenterol. 2017 Jul;52(7):777-787
pubmed: 28534191
Clin Exp Immunol. 2003 Oct;134(1):120-6
pubmed: 12974764
Gut. 2014 Apr;63(4):567-77
pubmed: 23468464
J Appl Microbiol. 2021 Dec;131(6):3018-3031
pubmed: 34008889
Psychometrika. 2017 Dec;82(4):1052-1077
pubmed: 27738957
Front Microbiol. 2020 Nov 05;11:591568
pubmed: 33224127
Immunity. 2016 Mar 15;44(3):647-658
pubmed: 26944199
Front Microbiol. 2019 Mar 21;10:438
pubmed: 30949136
Immunity. 2017 Jul 18;47(1):118-134.e8
pubmed: 28709802
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Front Microbiol. 2020 Jul 14;11:1553
pubmed: 32765449
Sci Rep. 2017 Apr 12;7(1):851
pubmed: 28404987
J Crohns Colitis. 2020 Jan 1;14(1):4-22
pubmed: 31711158
Dig Dis Sci. 2013 Nov;58(11):3144-55
pubmed: 24048682
J Dermatol. 2017 Aug;44(8):e206-e207
pubmed: 28432713
J Immunol Res. 2021 May 29;2021:9117805
pubmed: 34195297
Gut Microbes. 2021 Jan-Dec;13(1):1-17
pubmed: 33557671
Inflamm Bowel Dis. 2010 Jul;16(7):1097-107
pubmed: 20014018
Microorganisms. 2020 Mar 20;8(3):
pubmed: 32244928
PLoS One. 2012;7(6):e39242
pubmed: 22768065
Curr Opin Pharmacol. 2020 Oct;54:51-58
pubmed: 32947075
mBio. 2018 Mar 13;9(2):
pubmed: 29535202
J Clin Microbiol. 2014 Feb;52(2):398-406
pubmed: 24478468
J Clin Med. 2021 Mar 03;10(5):
pubmed: 33802483
Gut. 2004 Jan;53(1):91-8
pubmed: 14684582
J Anim Ecol. 2020 Jul;89(7):1549-1558
pubmed: 32248522
J Clin Invest. 2003 Sep;112(5):693-706
pubmed: 12952918
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Curr Med Res Opin. 2020 Apr;36(4):595-606
pubmed: 31960724
Frontline Gastroenterol. 2019 May 29;11(2):111-116
pubmed: 32133109
Cells. 2019 Jul 13;8(7):
pubmed: 31337064
Aliment Pharmacol Ther. 2013 Jul;38(2):151-61
pubmed: 23725320
Cells. 2021 Nov 16;10(11):
pubmed: 34831411
Gut. 2022 May;71(5):1020-1032
pubmed: 35105664
Aliment Pharmacol Ther. 2018 Apr;47(7):896-905
pubmed: 29430672
Microorganisms. 2019 Dec 01;7(12):
pubmed: 31805744
Gut. 2005 Apr;54(4):479-87
pubmed: 15753532
Gastroenterology. 2008 Oct;135(4):1130-41
pubmed: 18706417
Int J Mol Med. 2008 Aug;22(2):181-5
pubmed: 18636171
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
PLoS One. 2011;6(11):e27961
pubmed: 22132181
PLoS One. 2013 Jun 17;8(6):e66019
pubmed: 23799070
Gut. 2009 Jun;58(6):777-89
pubmed: 19201776
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Int J Mol Sci. 2021 Oct 19;22(20):
pubmed: 34681921
Aliment Pharmacol Ther. 2019 Dec;50(11-12):1159-1171
pubmed: 31648369